Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Alan P. Lyss, MD

    News

    New targeted treatments are major advances for HER2-positive breast cancer

    Author:
    Alan P. Lyss, MD
    Publish date: May 21, 2021

    Dr. Alan Lyss reviews data on HER2-targeted therapies in breast cancer.

    • Read More

    Article

    The power and promise of social media in oncology

    Author:
    Alan P. Lyss, MD
    Publish date: May 3, 2021

    Dr. Alan Lyss describes a recent presentation on the role of social media in oncology.

    • Read More

    Article

    IMvigor130: A treasure trove of data for urothelial carcinoma

    Author:
    Alan P. Lyss, MD
    Publish date: April 23, 2021

    Dr. Alan Lyss reviews updated results with atezolizumab in locally advanced or metastatic urothelial carcinoma.

    • Read More

    Article

    Leveraging the microbiome to enhance cancer treatment

    Author:
    Alan P. Lyss, MD
    Publish date: April 16, 2021

    Dr. Alan Lyss reviews research suggesting that an antibiotic can improve the efficacy of radiotherapy.

    • Read More

    Article

    Steroid-refractory pneumonitis from ICIs: Experience at major centers

    Author:
    Alan P. Lyss, MD
    Publish date: April 9, 2021

    Dr. Alan Lyss explores two studies of patients with steroid-resistant or refractory pneumonitis resulting from...

    • Read More

    Article

    mCODE: Improving data sharing to enhance cancer care

    Author:
    Alan P. Lyss, MD
    Publish date: March 12, 2021

    Dr. Alan Lyss explores mCODE, a project designed to improve the sharing of data from cancer patients.

    • Read More

    Article

    Genetic testing for breast and ovarian cancer: What has changed and what still needs to change?

    Author:
    Alan P. Lyss, MD
    Publish date: March 5, 2021

    Dr. Alan Lyss reviews a study that revealed trends in genetic testing over time.

    • Read More

    Opinion

    Enfortumab vedotin offers hope to poor-prognosis patients with advanced urothelial cancer

    Author:
    Alan P. Lyss, MD
    Publish date: February 26, 2021

    EV is an antibody-drug conjugate directed against nectin-4, an immunoglobulin-like cell adhesion molecule that...

    • Read More

    Article

    How has the pandemic affected rural and urban cancer patients?

    Author:
    Alan P. Lyss, MD
    Publish date: February 18, 2021

    A survey suggests the pandemic has impacted rural and urban cancer patients somewhat differently.

    • Read More

    Article

    X-ray vision: Using AI to maximize the value of radiographic images

    Author:
    Alan P. Lyss, MD
    Publish date: February 16, 2021

    Dr. Alan Lyss reviews studies using artificial intelligence to predict lung cancer risk and outcomes.

    • Read More

    Article

    ctDNA outperforms CEA in colorectal cancer

    Author:
    Alan P. Lyss, MD
    Publish date: January 26, 2021

    Circulating tumor DNA testing bested carcinoembryonic antigen testing in a study of patients with colorectal...

    • Read More

    Article

    RSClin: A new tool for ‘TAILOR-ing’ treatment in early breast cancer

    Author:
    Alan P. Lyss, MD
    Publish date: January 14, 2021

    Dr. Alan P. Lyss describes RSClin, a tool for estimating the risk of distant relapse in breast cancer. ...

    • Read More

    Article

    DART trial hits the target in angiosarcoma

    Author:
    Alan P. Lyss, MD
    Publish date: December 24, 2020

    Dr. Alan Lyss reviews results of the DART trial and highlights the value of clinical trials for rare cancers....

    • Read More

    Article

    How should we evaluate the benefit of immunotherapy combinations?

    Author:
    Alan P. Lyss, MD
    Publish date: December 10, 2020

    Dr. Alan Lyss examines how new endpoints, novel study design, and other methods might better quantify the...

    • Read More

    Article

    Using telehealth to deliver palliative care to cancer patients

    Author:
    Alan P. Lyss, MD
    Publish date: November 17, 2020

    Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.

    • Read More

    Pages

    • 1
    • 2
    • 3
    • 4
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery